Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

Diagnostic and Prognostic Markers in Low-Grade Gliomas

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01004523

Enrollment

135

Registered

2009-10-30

Start date

1995-12-31

Completion date

2013-03-31

Last updated

2016-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain and Central Nervous System Tumors

Keywords

childhood low-grade cerebellar astrocytoma, childhood low-grade cerebral astrocytoma, childhood mixed glioma, adult mixed glioma, adult diffuse astrocytoma, childhood oligodendroglioma, adult oligodendroglioma

Brief summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue and blood samples from patients with low-grade glioma.

Detailed description

OBJECTIVES: * Evaluate the diagnostic and prognostic relevance of alterations of specific chromosomes and chromosomal regions including 7, 9p, 10p, 10q, 13q, 17p, 17q, 19q, 22q, X, and Y, using PCR analysis of microsatellite repeats and FISH. * Evaluate the diagnostic and prognostic relevance of DNA ploidy by flow cytometric analysis; compare with ploidy determination by FISH. * Assess the diagnostic and prognostic relevance of various markers of cellular proliferation and cellular function including flow cytometric determination of %S-phase, %G2M, and immunohistochemical evaluation of PCNA, Ki-67, and p53.

Interventions

GENETICfluorescence in situ hybridization

GENETICloss of heterozygosity analysis

GENETICpolymerase chain reaction

OTHERflow cytometry

OTHERimmunohistochemistry staining method

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Paraffin-embedded tumor tissue blocks of patients enrolled in NCCTG 86-72-51 or 93-72-02 and who had the diagnosis of low-grade glioma. 2. Patients who have the diagnosis of low-grade glioma with an available paraffin- embedded tumor tissue block enrolled in prospective NCCTG and Mayo studies.

Design outcomes

Primary

Measure	Time frame
DNA ploidy by FISH and flow cytometry	baseline
Alterations in chromosomes 7, 9p, 10, 17, 19q, X, or Y as determined by FISH	baseline
Loss of chromosomal materials in chromosomes 9p, 10, 13, 17, or 22 by PCR analysis	baseline
Levels of PCNA, Ki-67 (MIB-1), or mutated p53 by immunostaining with monoclonal antibodies	baseline
Percentage of cells in S-phase or G2M-phase as measured by flow cytometry	baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026